HOME >> MEDICINE >> NEWS
Novel antibiotic provides rapid relief from symptoms of tonsillitis/pharyngitis, study shows

Ketek (telithromycin), a novel compound from a new family of antibiotics, administered once daily for five days to patients suffering from tonsillitis/pharyngitis, provided equivalent clinical and bacteriological outcomes as those observed in patients receiving a 10-day course of treatment with penicillin V, a new study shows.

The more rapid symptom relief achieved with Ketek, the first antibiotic from the ketolide family to be developed for clinical use, may suggest a potential for a faster return to usual activities, and fewer days lost from work or school, for people with tonsillitis/pharyngitis resulting from group A b-haemoliytic streptococcus (GABHS) bacteria. GABHS is the most common bacterial cause of tonsillitis/pharyngitis.

The study results, reported today at the 11th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) meeting in Istanbul, Turkey, were among several scientific presentations involving Ketek.

"This is an important study as it demonstrates the clinical and bacteriological effectiveness and symptom relief of Ketek in treating what is a very common upper respiratory tract infection," said Dr. Joanne Chang, Aventis Pharma.

The double-blinded study enrolled 396 patients between the ages of 15 and 65 with clinical signs and symptoms of acute tonsillopharyngitis, and who either had a positive streptococcal A antigen test or a positive throat culture for GABHS. These patients were randomized (198 patients to each group) to receive either 800 mg once daily Ketek followed by placebo for five days, or penicillin V 500 mg three-times daily for 10 days. Clinical and bacteriological outcomes were assessed at post-therapy (days 16-21) and late post-therapy (days 38-45).

At the post-therapy visit, bacteriological outcome was satisfactory in 79.7 percent and 79.3 percent of patients, and clinical cure was achieved in 85.9 percent and 85.8 percent of patients in the Ketek (198 patients) and penicillin V (197
'"/>

Contact: Liz Rickard
elizabeth.rickard@ketchum.com
44-0-20-7611-3633
Ketchum
4-Apr-2001


Page: 1 2

Related medicine news :

1. Novel therapy tested in mice could chase away cat allergies
2. Novel antibiotic shows promise in shortening treatment duration of tuberculosis
3. Novel p53 gene-based therapy boosts immune system and reduces tumor size
4. Novel drugs help solve Gleevec resistance
5. Novel imaging technique shows abnormal brain anatomy in children with ADHD
6. Novel drug-antidote strategy provides greater control of drug action
7. Novel imaging technique shows lymph nodes, metastases in breast cancer without surgery
8. Novel delivery method for nutrients wins Kaye Innovation Award for Hebrew university students
9. Novel vitamin discovery offers clues for cancer chemotherapy and lipid disorders
10. Novel findings about neovessel formation
11. Novel MRI technique provides clear images of blood flow

Post Your Comments:
(Date:5/4/2015)... Visiopharm, the leader in image analysis for ... private round of financing with NorthCap Partners . ... assist Visiopharm to further accelerate business growth and strengthen ... driven diagnostic digital pathology solutions. , "It has been ... solution has energized the pathologists, and how fast ...
(Date:5/4/2015)... 05, 2015 The National Association ... as a 2015-2016 inductee into its VIP Woman ... prestigious distinction for leadership in business. NAPW is the ... more than 700,000 members and over 200 operating Local ... important honor,” says NAPW President Star Jones. “Her perseverance, ...
(Date:5/4/2015)... The National Association of Professional Women ... 2015-2016 inductee into the NAPW VIP Woman of the ... for leadership in oral healthcare. NAPW is the nation's ... than 700,000 members and over 200 operating Local Chapters. ... group of professional women," said NAPW President Star Jones. ...
(Date:5/4/2015)... May 04, 2015 During 2015-2019, the ... 7.7% CAGR. Currently, the European and APAC probiotic markets ... the North American probiotic market lags behind owing to ... , The North American probiotic market is led ... followed by Canada and Mexico. The North American market ...
(Date:5/4/2015)... May 04, 2015 Malibu Biotech ... antiseptic breath spray. KissSafe™ is the first personal ... safer experience while adding fresh breath appeal. KissSafe™ ... effectively kills germs in the mouth and oral ... contains ingredients that possess additional wellness benefits. KissSafe’s ...
Breaking Medicine News(10 mins):Health News:Visiopharm Closes Investment Round to Grow Diagnostic Digital Pathology Business 2Health News:Visiopharm Closes Investment Round to Grow Diagnostic Digital Pathology Business 3Health News:NAPW Inducts Patti Hommes, Director of Advancement Services, Springside Chestnut Hill Academy, a 2015-2016 Professional Woman of the Year Circle 2Health News:National Association of Professional Women Inducts Elizabeth Moncada, Owner, Moncada Center for Orofacial Pain, into its 2015-2016 VIP Woman of the Year Circle 2Health News:North America Probiotic Market to Increase by 2019, Announces MicroMarketMonitor in Its New Research Report Recently Published at MarketPublishers.com 2Health News:80 Million Germs from Kissing - Introducing KissSafe™ 2
(Date:5/4/2015)... , May 4, 2015 Thirty-six million ... seek help. During May – National Hearing Month – ... could be missing out on the sounds of spring, ... trees. To ensure that you won,t be ... color our world, Oticon, Inc. offers practical advice: ...
(Date:5/4/2015)... , May 4, 2015  Impax Laboratories, Inc. (NASDAQ: ... key executive leadership roles, appointing  Donna M. Hughes, as ... Penza , as Senior Vice President, Chief Compliance Officer. ... Impax,s President and Chief Executive Officer, Fred Wilkinson ... Deborah have joined the Impax team," said Fred ...
(Date:5/4/2015)... Bayer HealthCare (Bayer) has entered into an ... ISIS ) on ISIS-FXI Rx, an antisense investigational ... Under the agreement Bayer will further develop and commercialize ... need. As part of the clinical development program, Bayer ... in an appropriate patient community. "Bayer ...
Breaking Medicine Technology:It's Better Hearing Month 2Impax Strengthens Leadership Team by Adding New Senior Vice Presidents for Human Resources and Compliance 2Impax Strengthens Leadership Team by Adding New Senior Vice Presidents for Human Resources and Compliance 3Bayer Licenses Investigational ISIS FXI(Rx) from Isis Pharmaceuticals to Develop and Commercialize for the Prevention of Thrombosis 2Bayer Licenses Investigational ISIS FXI(Rx) from Isis Pharmaceuticals to Develop and Commercialize for the Prevention of Thrombosis 3
Cached News: